These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24205731)

  • 1. [An inhibitor of intestinal cholesterol transporter].
    Sano M
    Nihon Rinsho; 2013 Sep; 71(9):1661-6. PubMed ID: 24205731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal sterol transporters and cholesterol absorption inhibition.
    Davis HR; Tershakovec AM; Tomassini JE; Musliner T
    Curr Opin Lipidol; 2011 Dec; 22(6):467-78. PubMed ID: 22101558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe: cholesterol lowering and beyond.
    Bays HE; Neff D; Tomassini JE; Tershakovec AM
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
    Ahmed MH; Byrne CD
    Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
    Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
    Davis HR; Veltri EP
    J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
    Kater AL; Batista MC; Ferreira SR
    Metabolism; 2010 Jun; 59(6):921-6. PubMed ID: 20199786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
    Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF
    J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.